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NF-Y Behaves as a Bifunctional 
Transcription Factor That Can Stimulate 
or Repress the FGF-4 Promoter 
in an Enhancer-Dependent Manner 
CORY T. BERNADT,*t TAMARA NOWLING,* 1 MATTHEWS. WIEBE,*t2 AND ANGIE RIZZINO*t 
*Eppley Institute for Research in Cancer and Allied Diseases, and the tDepartment of Pathology 
and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-6805 
NF-Y is a bifunctional transcription factor capable of activating or repressing transcription. NF-Y specifically 
recognizes CCAAT box motifs present in many eukaryotic promoters. The mechanisms involved in regulating 
its activity are poorly understood. Previous studies have shown that the FGF-4 promoter is regulated positively 
by its CCAAT box and NF-Y in embryonal carcinoma (EC) cells where the distal enhancer of the FGF-4 gene 
is active. Here, we demonstrate that the CCAAT box functions as a negative cis-regulatory element when cis-
regulatory elements of the FGF-4 enhancer are disrupted, or after EC cells differentiate and the FGF-4 enhancer 
is inactivated. We also demonstrate that NF-Y mediates the repression of the CCAAT box and that NF-Y 
associates with the endogenous FGF-4 gene in both EC cells and EC-differentiated cells. Importantly, we also 
determined that the orientation and the position of the CCAAT box are critical for its role in regulating the 
FGF-4 promoter. Together, these studies demonstrate that the distal enhancer of the FGF-4 gene determines 
whether the CCAAT box of the FGF-4 promoter functions as a positive or a negative cis-regulatory element. In 
addition, these studies are consistent with NF-Y playing an architectural role in its regulation of the FGF-4 
promoter. 
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Immunoprecipitation 
TRANSCRIPTIONAL regulation of gene expression 
involves the proper activation and repression of spe-
cific genes. This process is controlled by sequence-
specific transcription factors binding to promoters and 
enhancers and interacting with co-regulators, chroma-
tin remodeling complexes, and/or components of the 
basal transcriptional machinery (34,38,65). Many tran-
scription factors activate transcription, whereas others 
repress it_ However, several transcription factors are 
bifunctional and act either as activators or as repres-
sors. Thyroid hormone receptors and retinoic acid re-
ceptors interact with a co-repressor complex to confer 
transcriptional repression in the absence of hormone 
(65). Upon hormone binding, the receptor undergoes 
a conformational change resulting in the dissociation 
of co-repressors and the recruitment of coactivators 
to activate transcription. Other bifunctional transcrip-
tion factors include YYl (43,81), NF-KB (90) and 
NF-Y (51,62,75,89). 
NF-Y is a ubiquitously expressed transcription fac-
tor that is composed of three subunits: NF-YA, NF-
YB, and NF-YC (also known as CBF-B, CBF-A, and 
CBF-C, respectively). Each subunit contains an evo-
lutionarily conserved HAP domain that is critical for 
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subunit interactions and DNA binding (30,45,77). 
NF-YA and NF-YC each possess large glutamine-
rich activation domains outside of the HAP domain 
(14,15,19). Located within the HAP domains of NF-
YB and NF-YC is a histone-fold motif that is found 
in all core histones and that mediates dimerization 
and contributes to DNA binding (3,4,4 7). NF-YB and 
NF-YC subunits dimerize to form a complex that as-
sociates with NF-YA (77). Once the trimer forms, it 
can bind specifically to CCAAT boxes, which are 
cis-regulatory elements found in either orientation in 
25-30% of eukaryotic promoters, and typically lo-
cated between 60 and I 00 bp upstream of the tran-
scriptional start site (11,52). Analysis of 178 NF-Y-
binding CCAAT boxes demonstrated that their orien-
tation and position relative to neighboring TATA 
boxes are not distributed randomly (52). This sug-
gests that CCAA T boxes and NF-Y may serve an 
important architectural role in the organization of 
promoters. In this regard, NF-Y is capable of bending 
DNA 60-80° (46,72), and it has been shown to inter-
act with components of the basal transcriptional ma-
chinery (5,16,26). Thus far, the role of NF-Y as an 
architectural factor when bound to CCAAT boxes has 
not been systematically tested by altering its position 
or orientation. 
The binding of NF-Y to gene promoters appears to 
be regulated carefully during cell growth and differ-
entiation. Although NF-Y is a ubiquitous transcrip-
tion factor, it may not bind to CCAAT boxes consti-
tutively. The binding of NF-Y to the promoter of 
several cell cycle genes fluctuates during the cell cy-
cle (12). In other cases, loss of NF-YA expression in 
terminally differentiated muscle cells results in the 
loss of a functional NF-Y complex (24,28). More-
over, decreased NF-YA expression has been reported 
after serum deprivation of fibroblasts (13), whereas 
an increase in NF-YA expression was observed dur-
ing monocyte maturation (55). Although CCAAT 
boxes function primarily as positive cis-regulatory el-
ements, CCAAT boxes negatively regulate transcrip-
tion in several promoters, and both the positive and 
the negative effects of these CCAAT boxes are likely 
to be mediated by NF-Y (9,27,29,31,39,51,75,85,89). 
Importantly, NF-Y has been shown to interact with 
coactivators (18,23,35,44) or co-repressors in differ-
ent promoters (27,63). It remains unclear what factors 
or other variables determine whether a CCAA T box 
and NF-Y will activate or repress transcription of a 
given gene. However, adjacent cis-regulatory ele-
ments have been shown to be required for the nega-
tive effect of CCAAT boxes (27,29). 
Transcription of the fibroblast growth factor-4 
(FGF-4) gene has been shown to be activated by a 
CCAAT box located in its promoter approximately 
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100 bp upstream of the transcription start site (41). 
The FGF-4 gene is differentially expressed during 
early embryogenesis (57,66), and gene targeting stud-
ies have shown that FGF-4 is essential for early de-
velopment and the survival of extraembryonic tissues 
(25,79,83). FGF-4 expression is restricted to cells 
of the inner cell mass at the late blastocyst stage, 
whereas cells of the extraembryonic endoderm, which 
are derived from the inner cell mass, do not express 
FGF-4 (57,66). Expression of FGF-4 is dependent on 
its promoter and a powerful downstream distal en-
hancer located within the untranslated region of the 
third and last exon (17,50). Binding motifs for known 
transcription factors have been identified in both the 
promoter and the enhancer. The cis-regulatory ele-
ments of the promoter include a TATA box, two GC 
boxes that bind Spl and Sp3 in vitro (40,48), and an 
inverted CCAAT box that binds NF-Yin vitro (41). 
The cis-regulatory elements identified within the en-
hancer include: two high mobility group (HMG) mo-
tifs, referred to as upstream HMG (USHMG) and 
downstream HMG (DSHMG), which bind Sox2 in 
vitro and in vivo (49,58,87); a POU motif that binds 
Oct-3 in vitro (50); and a GT box that binds Sp! and 
Sp3 in vitro ( 48). Sox2 and Oct-3 bind cooperatively 
to the DSHMG and POU motifs, respectively, to syn-
ergistically activate transcription of promoter/reporter 
gene constructs (1,2,58,59,87). In addition, the coac-
tivator p300 appears to mediate the effect of Sox2/ 
Oct-3 synergism (59,58), and p300 has been shown 
to associate with the endogenous FGF-4 enhancer in 
embryonal carcinoma (EC) cells (58). 
EC cells serve as an excellent model for studying 
the expression of FGF-4 during early development. 
These cells are similar both biochemically and mor-
phologically to cells of the inner cell mass (54). 
Moreover, transcription of the FGF-4 gene decreases 
substantially after EC cells undergo differentiation 
(64,69,82,86). The downregulation of the FGF-4 
gene is thought to be due, at least in part, to the de-
crease in Sox2 and Oct-3 that accompanies differenti-
ation (37,42,56,60,87). To better understand the regu-
lation of the FGF-4 gene in this model system, we 
addressed four questions in this study. First, does NF-
y bind to the FGF-4 promoter in EC cells? Second, 
if it does, does it remain associated with the FGF-4 
promoter in the differentiated cells, and does it influ-
ence the FGF-4 promoter when EC cells differentiate 
and transcription of the FGF-4 gene is downregu-
lated? Third, is the function of the CCAAT box de-
pendent on adjacent cis-regulatory elements in the 
FGF-4 promoter, in particular the two upstream GC 
boxes? Fourth, does the CCAAT box play an archi-
tectural role in the regulation of the FGF-4 promoter? 
Our results demonstrate that NF-Y binds to the en-
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dogenous FGF-4 promoter in both F9 EC cells and 
F9-differentiated cells. In addition, we show that, 
upon differentiation, the FGF-4 enhancer becomes 
inactive, the CCAAT box becomes a negative cis-
regulatory element, and NF-Y mediates the repres-
sion of the CCAA T box. Therefore, NF-Y can both 
activate and repress the FGF-4 promoter, and the role 
of NF-Y is dependent upon the FGF-4 enhancer. 
Moreover, we show that the CCAAT box can nega-
tively regulate transcription independent of the two 
upstream GC boxes. Finally, we demonstrate that the 
orientation and the position of the CCAAT box are 
critical for its regulatory role in FGF-4 promoter ac-
tivity. Collectively, our results address two important 
issues concerning NF-Y-mediated gene regulation. 
First, we demonstrate that the behavior of NF-Y and 
the CCAAT box of the FGF-4 promoter is regulated 
by an unexpected mechanism, specifically, by the 
downstream distal enhancer of the FGF-4 gene. Sec-
ond, we provide direct evidence that the position and 
the orientation of the CCAAT box critically affect its 
function. Thus, our data argue strongly that NF-Y can 
function in an architectural manner. 
MATERIALS AND METHODS 
Cell Culture and Conditions 
Mouse F9 EC cells were cultured on gelatinized 
dishes in Dulbecco's modified Eagle's medium (DMEM, 
Invitrogen, Carlsbad, CA) supplemented with 10% 
fetal bovine serum (FBS, HyClone, Logan, UT) and 
antibiotics, as described previously (68,70). Differen-
tiation of F9 EC cells was induced by treatment with 
5 µM retinoic acid (RA). Cells were cultured at 37°C 
in a humidified atmosphere of 5% C02 in air. 
Transient Transfection Assay 
F9 EC cells were seeded at 5 x 105 cells per 100-
mm dish. After 24 h, the cells were transfected with 
promoter/reporter gene constructs and expression vec-
tors by the calcium phosphate precipitation method 
(50). Following a 24-h incubation with the precipi-
tate, the cells were refed with DMEM + 10% FBS. 
Chloramphenicol acetyltransferase (CAT) and P-
galactosidase activities were determined 48 h after 
transfection, as described previously (50). For experi-
ments involving F9-differentiated cells, F9 EC cells 
were seeded at 1 x 105 cells per 100-mm dish in 
DMEM + 10% FBS and 5 µM RA and transfected 
with promoter/reporter gene constructs and expres-
sion vectors 72 h later. Following a 24-h incubation 
with the precipitate, the cells were refed with DMEM 
+ 10% FBS and 5 µM RA. CAT and P-galactosidase 
act1V1t1es were determined 72 h after transfection. 
Molar amounts of DNA were kept constant with the 
addition of null plasmid DNA, pCMV5. All transfec-
tions were normalized by addition of 1 µg of CMVP-
galactosidase (Clontech, Palo Alto, CA). All transfec-
tions were performed in duplicate. Error bars indicate 
the SD of either the fold induction or the relative 
CAT activity obtained by the compilation of multiple 
experiments as indicated in the figure legends. Data 
were evaluated for statistical significance using the 
Student's t-test. 
Plamid Constructs 
The following promoter/reporter constructs have 
been described elsewhere: 427T +E (also known as 
pKFGF427T+E) (48,73), 427T, CCAATmut+E (also 
known as -427T+E CCAATmut), CCAATmut (also 
known as -427T CCAATmut) (36), TKCat, TKCat+E, 
427T+EnGSp, GCmut (also known as 427T SplDP-
E), CCAATmut+EnGSp (also known as 427TCmut 
+EnGSp) (58), and GCmut+E (also known as SplDP) 
( 48). GCmut/CCAATmut contains mutations in both 
the GC boxes and the CCAAT box of the FGF-4 
promoter but lacks the enhancer and was constructed 
by removing the enhancer from 427TGC/Cmut+ 
EnGSp (58) by digestion and religation of the Sad 
sites flanking the enhancer. CCAATmut+EGTmut 
and CCAATmut+EHMGmut were constructed by iso-
lating the enhancers from Sp IE ( 48) and 427T + 
DSHMGmut (49), respectively, by digestion with 
Sad and ligating them into the Sacl site of CCAAT-
mut. 427TG4/CCAAT was constructed using PCR 
with 427T as the template and the following primers: 
upper primer, 5'-CCTCggatccGGAGGACAGTCC 
ACCGACCTGCGCCCCGGCTCCCAGG-3'; lowef 
primer, 5'-TCACCGggatccGAGGAGGCGCGGGCcZ 
GGGCGGTGGC-3'. Lower case sequence denote!; 
BamHI sites, sequence in bold denotes the Gal4 bind-
ing site, and the underlined sequence is wild-typ~ 
promoter sequence. This PCR amplified the entir~ 
plasmid except for the CCAAT box, which was re~ 
placed by the Gal4 binding site. The BamHI sites 
were then used to circularize the plasmid. Upstream 
CCAAT+E, reversed CCAAT+E, upstream CCAATI, 
I 
and reversed CCAA T were generated by the Quick[ 
Change method of mutagenesis (Stratagene, La Jolla; 
CA) using the promoter/reporter constructs CCAAT 
mut+E and CCAATmut, respectively. The following 
primer and its complement were used to replac~ 
sequence upstream of the two GC boxes with ~ 
CCAAT box in the constructs upstream CCAAT +~ 
and upstream CCAAT: 5'-CAGCTCAAGTCAGTGK 
TTGGCAGAGCAGAAAGGTTCTGGCGG-3'. Th~ 





lowing primer and its complement were used to cre-
ate a CCAAT box in the opposite orientation of the 
original CCAA T box in the constructs reversed 
CCAAT+E and reversed CCAAT: 5'-GCGCCTCCT 
CCCCCGGTGCTGCCAATCACGCGACCTGC-3'. 
The sequence in bold denotes the inverted CCAAT 
box. 
The following expression plasmids were utilized: 
CMVGal4 and Gal4/Sox2 121-319 (59); the SV40-
Gal4 fusion vector, pM3 (74); Gal4/p300 1-2414 
(full-length p300 fused to the DNA binding domain 
of the yeast transcription factor Gal4) and Gal4/p300 
964-1922 (p300 amino acids 964-1922 fused to the 
DNA binding domain of Gal4) (88); pNF-YA29 (53); 
and pSG424-NF-YC Lil, which was received from 
Keiko Funa (Goteborg University) (32). CMVGal4/ 
NF-YA 1-261 was generated by amplifying amino 
acids 1-261 of NF-YA and inserting the amplified 
fragment into the HindIII site of CMVGal4 using the 
following primers: upper primer, 5' -AGCTaagcttAT 
GGAGCAGTATACGACAAACAGC-3'; lower primer, 
5 '-AGCTaagcttCTCTTCTTCCAGCATCTCTGCTC 
CAG-3'. The lowercase sequences denote HindIII 
sites. CMVGal4/NF-YB Li50-139 was made in two 
steps. The first step involved. amplifying the entire 
NF-YB sequence and inserting it into the BamHI site 
of CMVGal4 to create CMVGal4/NF-YB using the 
following primers: upper primer, 5'-CTACGTggatcc 
T ATGACAATGGACGGCGACAG-3'; lower primer, 
5'-CGAACTggatccTCATGAAAACTGAA TTTGCTG-
3'. The lowercase sequences denote BamHI sites. The 
second step involved amplifying the entire CMV-
Gal4/NF-YB sequence except for the sequence that 
encodes amino acids 50 to 139 of NF-YB. The fol-
lowing primers used for this step inserted a KpnI site 
to allow the amplified plasmid to be religated: upper 
primer, 5' -CCTCggtaccAAGTTCAGAGAGGCCA T 
GAAAG-3'; lower primer, 5'-CCTCggtaccACTTTC 
TTTTGAACCATTTG-3'. The lowercase sequences 
denote Kpnl sites. 
Chromatin Immunoprecipitation (Ch!P) 
ChIP was performed as follows. On day 1, F9 EC 
cells were seeded at a density of 2 x 105 on 100-mm 
dishes and induced to differentiate with 5 µM RA. 
On day 4, F9 EC cells were seeded at 2 x 106 cells 
per 100-mm dish. On day 5, cross-linking was per-
formed by addition of formaldehyde to the culture 
medium at a final concentration of 1 % for 10 min at 
room temperature. Cells were then washed and scraped 
into PBS containing 1 mM PMSF, 1 µg/ml aprotinin, 
and 1 µg/ml pepstatin A. Cells were lysed in SOS 
lysis buffer (1 % SDS, 10 mM EDTA, 50 mM Tris, 
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pH 8.1) containing 1 mM PMSF, 1 µg/ml aprotinin, 
and 1 µg/ml pepstatin A by adding 200 µl of lysis 
buffer per 1 x 106 cells. Following incubation on ice 
for 1 O min, the DNA was sheared to lengths between 
200 and 1000 bp by sonication, and cell debris was 
pelleted. Aliquots (200 µl) of the sonicated cell su-
pernatant were diluted IO-fold by the addition of 
ChIP dilution buffer (0.01 % SDS, 1.1 % Triton X-
100, 1.2 mM EDTA, 16.7 mM Tris-HCI, pH 8.1, 167 
mM NaCl) plus 1 mM PMSF, 1 µg/ml aprotinin, and 
l µg/ml pepstatin A. To reduce nonspecific back-
ground, the samples were precleared with 80 µl of 
salmon sperm DNA/protein A agarose (50% slurry) 
(Upstate Biotechnology, Lake Placid, NY) for 30 min 
at 4 °C with rotation. The precleared samples were 
then incubated with 15 µg NF-YA antibody (H-209; 
Santa Cruz Biotechnology, Inc., Santa Cruz, CA), 15 
µg NF-YB antibody (FL-207; Santa Cruz Biotechnol-
ogy, Inc.), or 15 µg preimmune normal rabbit IgG 
(Santa Cruz Biotechnology, Inc.) at 4 °C with rotation 
overnight. Immune complexes were collected with 60 
µl of salmon sperm DNA/protein A agarose (50% 
slurry) for 1 h at 4°C with rotation. The samples were 
washed once with low-salt wash buffer (0.1 % SDS, 
1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, 
pH 8.1, 150 mM NaCl), high-salt buffer (0.1 % SDS, 
1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, 
pH 8.1, 500 mM NaCl), and LiCl wash buffer (2.25 
M Li Cl, 1 % IGEPAL-CA630, 1 % deoxycholic acid, 
1 mM EDTA, 10 mM Tris, pH 8.1) and twice with 
TE buffer (10 mM Tris-HCI, 1 mM EDTA, pH 8.0). 
Complexes were eluted by two incubations with 250 
µl of elution buffer (1 % SOS, 0.1 M NaHC03) at 
room temperature for 10 min with rotation. NaCl was 
added to a final concentration of 0.2 M, and the sam-
ples were incubated at 65°C for 4 h to reverse the 
cross-links. The samples were treated with 20 µg of 
Proteinase K for 1 h at 45°C after the addition of 10 
µl 0.5 M EDTA and 20 µl 1 M Tris-HCI, pH 6.5. 
DNA was purified using the GeneClean turbo kit (Q 
Biogene, Carlsbad, CA) following the manufacturer's 
directions. In studies not shown, ChIP analysis was 
performed with HDACl antibodies (H-51, Santa Cruz 
Biotechnology). 
The following primer pairs were used to detect the 
presence of DNA fragments containing the indicated 
regions. FGF-4 promoter: FGFproU2, 5'-GTAAGG 
AAGGAGCACAGGAGAT-3' and FGFproL3, 5'-
CAGACCTAAGTAGCGAGAGCAA. Tf3R-II pro-
moter: T~RIIpro U, 5' -ACACCACTTTCGAGCTTG 
TTTTGC and Tf3RIIproL, 5'-CGCGAGTGACTCA 
CTCATCAAC. FGF-4 5' region: FGF5'U, 5'-ACCT 
CACCTGTGCCCTGTTGAAT-3' and FGF5'L, 5'-
GTGCTCATCTCCCCAGACTGTTTCT-3'. PCR was 
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performed on equivalent volumes of each sample and 
analyzed at multiple cycles. Results are presented for 
one cycle. 
RESULTS 
The FGF-4 Enhancer ls Inactive 
and the FGF-4 Promoter Can Be Activated 
in F9-Differentiated Cells 
The transcription of the FGF-4 gene depends on a 
powerful distal enhancer located 3 kb downstream of 
the transcription start site. In F9 EC cells, the FGF-
4 enhancer increases the activity of FGF-4 promoter/ 
reporter gene constructs over 50-fold (17,50). Previ-
ous studies demonstrated that the activity of FGF-4 
promoter/reporter gene constructs is greatly reduced 
after differentiation. Although the FGF-4 enhancer 
appears to be inactivated after EC cells differentiate 
(17,50), it was unclear whether the enhancer is com-
pletely inactivated after differentiation and whether 
differentiation influences the function of the FGF-4 
promoter. To address the first issue, we tested the 
effect of the 316 bp FGF-4 enhancer on the heterolo-
gous herpes simplex virus thymidine kinase (TK) 
promoter. We chose the TK promoter because it is 
active in F9-differentiated cells, and because this pro-
moter is stimulated five- to sixfold by the FGF-4 en-
hancer in F9 EC cells (58). Here we show that the 
FGF-4 enhancer hardly affected the TK promoter in 
F9-differentiated cells (Fig. IA). This argues that the 
FGF-4 enhancer exhibits little or no activity after EC 
cells differentiate. To determine whether differentia-
tion influences the function of the FGF-4 promoter, 
we initially tested whether the FGF-4 promoter can 
be activated in F9-differentiated cells. For this pur-
pose, we examined whether the activation domains of 
Sox2 and p300 could stimulate the FGF-4 promoter 
in F9-differentiated cells, because both factors have 
been shown to activate the FGF-4 promoter (37,58, 
87). For these studies, we utilized the promoter/re-
porter gene construct 427T +EnGSp, in which the 
CAT reporter gene is under the control of the FGF-4 
promoter and a modified FGF-4 enhancer (58). More 
specifically, in this construct the DSHMG and POU 
motifs of the enhancer have been replaced by a Gal4 
DNA binding site, allowing Gal4-chimeric fusion 
proteins to bind to the FGF-4 enhancer. Cotransfec-
tion of 427T +EnGSp with an expression plasmid for 
Gal4/Sox2 or Gal4/p300 resulted in over a 150-fold 
induction in reporter gene activity in F9-differentati-
ated cells (Fig. 1B and C, respectively). This is simi-
lar to the 150-fold induction that is observed with 
Gal4/Sox2 in F9 EC cells (Fig. ID). These results 
demonstrate that the FGF-4 promoter can be acti-
vated to comparable levels in both F9 EC and F9-
differentiated cells. Therefore, inactivation of the 
FGF-4 gene in F9-differentiated cells appears to be 
due primarily to loss of enhancer function and does 
not appear to be due to an FGF-4 promoter that is 
irreversibly repressed. 
The CCAAT Box of the FGF-4 Promoter 
Can Function as a Positive or a Negative 
cis-Regulatory Element 
Several cis-regulatory elements have been identi-
fied in the FGF-4 promoter, including an inverted 
CCAAT box and a pair of GC boxes (41,48). Previ-
ous studies have shown that disruption of the CCAAT 
box and the GC boxes in FGF-4 promoter/reporter 
gene constructs lowers reporter gene activity when 
these constructs and their wild-type counterparts are 
compared in F9 EC cells. In the case of the CCAAT 
box, its disruption can reduce FGF-4 promoter activ-
ity as much as 70% (41,48). Surprisingly, in F9-
differentiated cells, disruption of the CCAAT box re-
sulted in a twofold increase in reporter gene activity 
relative to a construct with a wild-type promoter (Fig. 
2A). This finding suggests that the CCAAT box func-
tions as a negative cis-regulatory element in F9-
differentiated cells. Because the FGF-4 enhancer is 
inactivated in F9-differentiated cells, we examined 
the effect of disrupting the CCAA T box in F9 EC 
cells utilizing promoter/reporter gene constructs that 
do not contain the FGF-4 enhancer. In this context, 
disruption of the CCAAT box resulted in a four- to 
fivefold increase in reporter gene activity (Fig. 2B). 
This observation argues that the CCAAT box func-
tions as a negative regulatory element in the absence 
of the FGF-4 enhancer. This property is unique to 
the CCAA T box, because disruption of the two GC 
boxes (GCmut) resulted in a decrease in promoter ac-
tivity when the FGF-4 enhancer was not present (Fig. 
2B). Moreover, the ability of the CCAAT box to 
function negatively in the absence of the enhancer 
was not impaired when the two GC boxes were dis-
rupted. This was illustrated by the increase in activity 
of the construct in which both the CCAAT box and 
the two GC boxes were disrupted (GCmut/CCAAT-
mut) relative to the construct in which only the two 
GC boxes had been disrupted (GCmut) (Fig. 2B). Im-
portantly, our studies indicate that disruption of the 
CCAAT box did not create a sequence for a positive 
acting factor. In this regard, similar results were ob-
tained when a different DNA sequence was used to 
disrupt the CCAAT box (data not shown). Moreover, 
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Figure I. The FGF-4 enhancer is inactive and the FGF-4 promoter can be activated in F9 differentiated cells. (A) Transfection of F9-
differentiated cells with 15 µg of TKCat or TKCat+E. Results are presented as CAT expression relative to the activity of TKCat, which was 
set to 1. This experiment was performed three times. The data shown are the compilation of the three experiments, and the standard deviation 
for each condition is represented by error bars. Analysis of the data by the Student's t-test indicated that the activity of TKCat+E was not 
significantly different than the activity of TKCat. (B) Transfection of F9-differentiated cells with 15 µg of 427T +EnGSp alone or with I µg 
of a vector expressing Gal4 or Gal4/Sox2. Results are presented as fold induction over the activity of 427T +EnGSp alone, which was set 
to I . This experiment was performed two times. The data shown ate the compilation of the two experiments, and the standard deviation for 
each condition is represented by error bars. Analysis of the data by the Student's t-test indicated that the activation by Gal4/Sox2 was 
significant with a p-value of Jess than 0.05. (C) Transfection of F9-differentiated cells with 15 µg of 427T+EnGSp alone or with 5 µg of a 
vector expressing Gal4 or Gal4/p300. Results are presented as fold induction over the activity of 427T +EnGSp alone, which was set to I. 
This experiment was performed three times. The data shown are the compilation of the three experiments, and the standard deviation for 
each condition is represented by error bars. Analysis of the data by the Student's I-test indicated that the activation by Gal4/p300 was 
significant with a p-value of less than 0.05. (D) Transfection of F9 EC cells with 15 µg of 427T +EnGSp alone or with 5 µg of a vector 
expressing Gal4 or Gal4/Sox2. Results are presented as fold induction over the activity of 427T +EnGSp alone, which was set to I. This 
experiment was performed five times. The data shown are the compilation of the five experiments, and the standard deviation for each 
condition is represented by error bars. Analysis of the data by the Student's t-test indicated that the activation by Ga14/Sox2 was significant 
with a p-value of less than 0.05. 
although the CCAAT box motif of the FGF-4 pro-
moter has been shown to bind NF-Y in vitro ( 41), no 
DNA/protein complexes formed in a gel electropho-
retic mobility shift assay in which the DNA probe 
contained the mutant CCAAT box sequence (data not 
shown). Collectively, these results argue that the 
CCAAT box of the FGF-4 promoter can function 
both as a positive and a negative cis-regulatory ele-
ment, and that the function of the CCAAT box is 
dependent upon the activity of the FGF-4 enhancer. 
Several important cis-regulatory elements have 
been identified in the FGF-4 enhancer, including two 
HMG motifs that bind Sox2, a POU motif that binds 
Oct-3, and a GT box that binds Spl and Sp3 (40,48-
50,87). Moreover, several studies have shown that at 
least two of the cis-regulatory elements of the FGF-
4 enhancer work together to cooperatively activate 
the FGF-4 promoter (1,2,49,59,87). To determine 
which of these cis-regulatory elements influence the 
function of the CCAAT box in F9 EC cells, we uti-
lized promoter/reporter gene constructs in which the 
different cis-regulatory elements of the enhancer 
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Figure 2. The FGF-4 CCAAT box functions as a negative cis-regulatory element in the absence of a functional enhancer. (A) Transfection 
of F9-differentiated cells with 15 µg of 427T +E or CCAA Tmut+E. Results are presented as fold induction over the activity of 427T +E, 
which was set to 1. This experiment was performed four times. The data shown are the compilation of the four experiments, and the standard 
deviation for each condition is represented by error bars. Analysis of the data by the Student's t-test indicated that the activity of 
CCAATmut+E was significantly greater than the activity of 427T +E with a p-value of less than 0.05. (A) Transfection of F9 EC cells with 
15 µg of 427T, CCAATmut, GCmut, or GCmut!CCAA Tmut. Results are presented as fold induction over the activity of 427T, which was 
set to 1. The fivefold increase indicates fold induction of CCAATmut relative to 427T, and the fourfold increase indicates fold induction of 
GC/CCAA Tmut relative to GCmut. This experiment was performed three times. The data shown are the compilation of the three experiments, 
and the standard deviation for each condition is represented by error bars. Analysis of the data by the Student's t-test indicated that the 
activity of CCAATmut was significantly greater than the activity of 427T with a p-value of less than 0.05, and the activity of GCmut/ 
CCAATmut was significantly greater than the activity of GCmut with a p-value of less than 0.05. 
were disrupted along with the CCAAT box. The ac-
tivities of these constructs were compared to con-
structs that contain a wild-type CCAAT box. Disrup-
tion of the CCAAT box in conjunction with the GT 
box, the DSHMG motif, or both the DSHMG and 
POU motifs each resulted in a two- to threefold in-
crease in reporter gene activity in F9 EC cells (Fig. 
3). Although this is less than the four- to fivefold in-
crease that is observed when the entire enhancer is 
absent, these findings argue that the GT box, the 
DSHMG motif, and the POU motif of the FGF-4 en-
hancer are required for the CCAA T box to function 
positively. Moreover, these findings argue that dis-
ruption of any of these cis-regulatory elements in the 
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Figure 3. The CCAAT box functions as a negative cis-regulatory element when different cis-regulatory elements of the FGF-4 enhancer 
are disrupted. Transfection of F9 EC cells with 15 µg of the indicated plasmid. Results are presented as fold induction over the activity of 
the constructs that contain a wild-type CCAA T box. Each construct that contains a wild-type CCAA T box was set to 1. This experiment 
was performed five times. The data shown are the compilation of the five experiments, and the standard deviation for each condition is 
represented by error bars. Analysis of the data by the Student's t-test indicated that the activity of CCAATmut+EGTmut was significantly 
greater than the activity of 427T+EGTmut with a p-value of less than 0.05, the activity of CCAATmut+EDSHMGmut was significant-
ly greater than the activity of 427T +EDSHMGmut with a p-value of less than 0.05, and the activity of CCAATmut+EnGSp was significantly 
greater than the activity of 427T +EnGSp with a p-value of less than 0.05. 
enhancer is sufficient to convert the CCAAT box of 
the FGF-4 promoter from a positive to a negative cis-
regulatory element. Interestingly, disruption of the 
CCAAT box in conjunction with the USHMG motif 
did not lead to an increase in reporter gene activity 
(data not shown). Thus, although the USHMG site 
contributes to the function of the FGF-4 enhancer 
(49), the USHMG site does not appear to influence 
the inhibitory behavior of the CCAAT box. 
The Coactivator p300 Converts the FGF-4 
CCAAT Box From a Negative to a Positive 
cis-Regulatory Element 
The transcription factors Sox2 and Oct-3 bind co-
operatively to the DSHMG and POU motifs of the 
FGF-4 enhancer to synergistically activate transcrip-
tion (1,59,87), and p300 appears to mediate this syn-
ergism (58,59). In addition, p300 can physically in-
teract with NF-Y in other promoters (23,44). These 
findings led us to test directly the effect of p300 on 
the function of the FGF-4 CCAAT box. For these 
studies, we employed the promoter/reporter gene 
construct 427T +EnGSp, which was described above, 
and the construct CCAATmut+EnGSp in which the 
CCAAT box of 427T+EnGSp has been disrupted. 
Cotransfection of F9 EC cells with CCAATmut+ 
EnGSp plus an expression plasmid for Gal4/p300 re-
sulted in 50% less reporter gene activity relative to 
the activation induced by Gal4/p300 with the con-
struct that contains a wild-type CCAAT box (Fig. 
4A). Importantly, previous studies demonstrated that 
Gal4/p300 activates the activity of 427T+EnGSp, but 
does not influence the activity of the parent construct, 
427T +E, which lacks a binding site for the yeast tran-
scription factor Gal4 (58). Therefore, the CCAAT 
box functions as a positive cis-regulatory element in 
response to p300, as well as the FGF-4 enhancer. It 
should be noted that the difference in the activity in-
duced by Gal4/p300 in F9 EC cells (approximately 
25-fold) (Fig. 4A) relative to the activity that is in-
duced by Gal4/p300 in F9-differentiated cells (ap-
proximately 150-fold) (Fig. IC) may be due to differ-
ent expression levels of Gal4/p300 or to differential 
posttranslational modifications of p300. In this re-
gard, the levels of p300 and its associated histone 
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Figure 4. The CCAAT box functions as a positive cis-regulatory element when p300 is tethered to the FGF-4 enhancer or in the presence 
of the SV40 enhancer. (A) Transfection of F9 EC cells with 15 µg of 427T+EnGSp or CCAATmut+EnGSp alone or with 5 µg of Gal4/ 
p300. Results are presented as fold induction over the activity of 427T+EnGSp, which was set to L This experiment was performed three 
times. The data shown are the compilation of the three experiments, and the standard deviation for each condition is represented by error 
bars. Analysis of the data by the Student's t-test indicated that the activation of CCAATrnut+EnGSp by Gal4/p300 was significantly less 
than the activation of 427T +EnGSp by Gal4/p300 with a p-value of less than 0.05. (B) Transfection of F9 EC and F9-differentiated cells 
with 15 µg of 427T+SV40E or CCAATmut+SV40E. Results are presented as CAT expression relative to the activity of 427T+SV40E, 
which was set to 1. This experiment was performed four times. The data shown are the compilation of the four experiments, and the 
standard deviation for each condition is represented by error bars. Analysis of the data by the Student's I-test indicated that the activity of 
CCAATmut+SV40E was significantly less than the activity of 427T+SV40E in both F9 EC and F9-differentiated cells with a p-value of 
less than 0.05. 
acetyltransferase activity have been reported to change 
after F9 EC cells undergo differentiation (10,61). To 
extend these findings, we examined whether the abil-
ity of the FGF-4 CCAAT box to function positively 
is specific for the FGF-4 enhancer. For this purpose, 
the FGF-4 enhancer of 427T+E was replaced with 
the heterologous SV40 enhancer to generate 427T+ 
SV40E. In F9 EC cells, the activities of 427T+E and 
427T+SV40E were similar (data not shown). We 
chose the SV 40 enhancer because it has been shown 
to mediate its effect, at least in part, through p300 
(21). Moreover, unlike the FGF-4 enhancer, the ac-
tivity of the SV40 enhancer increases with differenti-
ation (78). In the presence of the SV 40 enhancer, dis-
202 
ruption of the CCAA T box results in a decrease in 
reporter gene activity in both F9 EC and F9-differen-
tiatcd cells (Fig. 4B). Similar to the FGF-4 enhancer, 
the SV40 enhancer enables the CCAAT box to func-
tion as a positive cis-regulatory element. Together, 
these findings demonstrate that p300 is not only capa-
ble of activating the FGF-4 promoter, but it is also 
able to convert the FGF-4 CCAAT box from a nega-
tive to a positive cis-rcgulatory element. 
NF-Y Mediates the Repression 
of the FGF-4 CCMT Box 
Previous studies have shown NF-Y can bind to the 
FGF-4 CCAAT box sequence in vitro when nuclear 
extracts from F9 EC and F9-differentiated cells were 
examined by electrophoretic mobility shift assays 
( 41 ). Moreover, functional studies utilizing a domi-
nant negative form of NF-YA, NF-YA29, have shown 
NF-Y regulates FGF-4 promoter activity positively 
in F9 EC cells ( 41 ). NF-Y A29 contains a mutation in 
the DNA binding domain of NF-YA that allows NF-
y A29 to bind to the NF-YB-NF-YC dimer, but pro-
hibits the trimeric complex from binding to DNA 
(S3). Ectopic expression of NF-Y A29 in F9 EC cells 
reduces the activity of the promoter/reporter gene 
construct 427T+E by as much as 70% (41). In the 
current study, we used NF-YA29 to examine whether 
NF-Y represses the FGF-4 promoter in the absence 
of the FGF-4 enhancer. Cotransfection ofF9 EC cells 
with 427T and increasing amounts of NF-Y A29 re-
sulted in a dose-dependent increase in reporter gene 
activity (Fig. SA). In addition, we tested the effect of 
NF-Y A29 on 427T +E in F9-differentiated cells, 
where the FGF-4 enhancer is inactive. Again, in-
creasing amounts of NF-Y A29 led to a dose-depen-
dent increase in reporter gene activity (Fig. SB). 
Moreover, NF-YA29 had no effect on the FGF-4 
promoter/reporter construct in which the CCAAT box 
was disrupted. Together, these findings argue NF-Y 
is functionally involved in the repression of the FGF-
4 promoter in the absence of an active enhancer. 
To extend these studies, ChlP analyses were per-
formed to determine whether NF-Y is bound to the 
endogenous FGF-4 promoter before and after F9 EC 
cells differentiate. For this purpose, antibodies spe-
cific for NF-YA and NF-YB were used. We deter-
mined that both NF-Y antibodies immunoprecipitated 
chromatin fragments containing the FGF-4 gene pro-
moter from F9 EC cells, as well as from F9-differen-
tiated cells (Fig. SC). As a control, we demonstrated 
that NF-Y antibodies did not immunoprecipitate 
chromatin fragments from a region of the genome 3 
kb upstream of the FGF-4 promoter. To help confirm 
these studies, we examined the in vivo binding of 
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NF-Y to the promoter of the type II transforming 
growth factor-13 receptor (Tl3R-II) gene in both F9 
EC and F9-differentiated cells. The Tl3R-II promoter 
was used as a positive control, because NF-Y has 
been shown to positively regulate this promoter in 
F9-differentiated cells (6). Together, the functional 
studies with NF-YA29 and the ChIP analyses suggest 
that NF-Y binds to and activates the FGF-4 promoter 
in the presence of a functional enhancer, whereas in 
the absence of a functional enhancer, NF-Y binds to 
and represses the FGF-4 promoter. Currently, it is 
unclear how NF-Y represses the FGF-4 promoter. 
Recent studies argue that NF-Y can interact with the 
co-repressor, histone deacetylase 1 (HDACJ), and 
repress two other promoters (63,75). To examine 
whether this was the case for NF-Y and the FGF-4 
promoter, we performed ChIP analysis with an HDAC! 
antibody. However, in F9-differentiated cells, we did 
not observe enrichment of the FGF-4 promoter with 
antibodies that recognize HDACl (data not shown). 
Although NF-Y has been reported to repress tran-
scription from several promoters (27,51,63, 7S,89), no 
studies have mapped the region(s) of NF-Y responsi-
ble for repression. The transactivation domains of 
NF-Y have been mapped to glutamine-rich regions of 
NF-YA and NF-YC (14,lS,19). When isolated and 
fused to heterologous DNA binding domains, such as 
LexA and Ga14, these domains can activate transcrip-
tion. We used a similar approach to examine whether 
the individual subunits of NF-Y can mediate FGF-4 
promoter repression. For these studies, the promoter/ 
reporter gene construct 427T was modified to include 
a Gal4 DNA binding site in place of the CCAAT 
box in the FGF-4 promoter (427TG4/CCAAT). This 
modification allows Gal4/NF-Y fusion proteins to 
bind to the FGF-4 promoter. The HAP domain of 
each of the NF-Y subunits was removed from the 
Gal4/NF-Y expression plasmids used in this study 
(Gal4/NF-YA 1-261, Gal4/NF-YC ~l and Gal4/NF-
YB .1.S0-139) (Fig. 6A), because these domains are 
involved in subunit interactions and DNA binding 
(30,45,77). Cotransfection of F9 EC cells with 
427TG4/CCAAT and increasing amounts of an ex-
pression plasmid for Gal4/NF-Y A 1-261 or Gal4/ 
NF-YC .1.1 generated a dose-dependent increase in 
reporter gene activity (Fig. 6B and C, respectively). 
In contrast, expression of Gal4/NF-YB ~S0-139 ap-
pears to inhibit reporter gene activity (Fig. 6D). How-
ever, the decrease in activity is similar to the decrease 
that is observed with an expression plasmid for the 
Ga14 DNA binding domain alone. This result is most 
likely a reflection of the very weak activation poten-
tial of Gal4/NF-YB (lS,32). In this regard, when F9 
EC cells were cotransfected with Gal4/NF-YB .1.S0-
139 and the promoter/reporter gene construct 427T + 
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Figure 5. NF-Y is functionally involved in the repression of the FGF-4 promoter and binds to the endogenous FGF-4 promoter in F9 EC 
and F9-differentiated cells. (A) Transfection of F9 EC cells with 15 µg of 427T alone or with 0, 1, 2, or 4 µg of an expression plasmid for 
NF-Y A29. Results are presented as fold induction over the activity of 427T alone, which was set to I. This experiment was performed three 
times. The data shown are the compilation of the three experiments, and the standard deviation for each condition is represented by error 
bars. Analysis of the data by the Student's t-test indicated that the activation observed by the transfection of 2 µg of NF-Y A29 was 
significantly greater than the activity of 427T with a p-value of less than 0.05. (B) Transfection of F9-differentiated cells with 15 µg of 
427T +E alone or with 0, 2, 4, or 6 µg of an expression plasmid for NF-Y A29. Results are presented as fold induction over the activity of 
427T +E alone, which was set to 1. This experiment was performed two times. The data shown are the compilation of the two experiments, 
and the standard deviation for each condition is represented by error bars. Analysis of the data by the Student's r-test indicated that the 
activation observed by the transfection of 0.5 µg of NF-Y A29 was significantly greater than the activity of 427T +E with a p-value of less 
than 0.05. (C) Ch!P assays were performed on nontransfected F9 EC and F9-differentiated cells as described in Materials and Methods. NF-
Y-associated DNA fragments were immunoprecipitated with an antibody to NF-YA and NF-YB. Preimmune normal rabbit JgG was used 
as a negative control. DNA fragments were amplified using primers for the FGF-4 promoter, the TJ3R-II promoter, or a region upstream of 
















BERNADT ET AL. 
A 
262 317 346 I l I HAP NF-YA 
.--..---~~~~~~~~-, 
Ga14/NF-YA 1-261 j~G~·1~41L-------------' 
50 140 207 
NF-YB -~=='~~H""'A;.:_P_°';:I =====ii 
Gal4fNF-YB lJ.50-139 l!G!!a~t4L--.i..._ __ -->---~ 
37 120 
I HAP I 
335 
I NF-YC 


































0.00 ..L-____ __. _______ __._L... ___ -J _____ _ 
Gal4: 
Gal4/NF-YB ll.50-139: 1 
Figure 6. The individual subunits of NF-Y are not sufficient to repress the FGF-4 promoter. (A) Schematic representation of the Gal4/NF-
y fusion proteins compared to the wild-type protein. HAP, HAP domain. (B) Transfection of F9 EC cells with 15 µg of 427TG4/CCAAT 
alone or with 0, 1, 2.5, or 5 µg of an expression plasmid for Ga14/NF-YA 1-261. Results are presented as fold induction over the activity 
of 427TG4/CCAAT, which was set to 1. This experiment was performed three times. The data shown are the compilation of the three 
experiments, and the standard deviation for each condition is represented by error bars. Analysis of the data by the Student's t-test indicated 
that the activation observed by the transfection of I µg of Gal4/NF-Y A 1-261 was significantly greater than the activity of 427TG4/CCAAT 
with a p-value of less than 0.05. (C) Transfection of F9 EC cells with 15 µg of 427TG4/CCAAT alone or with 0, 1, 2, or 4 µg of an 
expression plasmid for Gal4/NF-YC LI.I. Results are presented as fold induction over the activity of 427TG4/CCAA T, which was set to 1. 
This experiment was performed four times. The data shown are the compilation of the four experiments, and the standard deviation for each 
condition is represented by error bars. Analysis of the data by the Student's t-test indicated that the activation observed by the transfection 
of 1 µg of Gal4/NF-YC Ll.l was significantly greater than the activity of 427TG4/CCAAT with a p-value of less than 0.05. (D) Transfection 
of F9 EC cells with 15 µg of 427TG4/CCAAT alone or with 0, 0.5, 1, or 2 µg of an expression plasmid for Gal4 or Ga14/NF-YB Ll.50-139. 
Results are presented as CAT expression relative to the activity of 427TG4/CCAAT, which was set to 1. This experiment was performed 
three times. The data shown are the compilation of the three experiments, and the standard deviation for each condition is represented by 
error bars. Analysis of the data by the Student's t-test indicated that the decrease in CAT activity observed by the transfection of 2 µg of 
Gal4/NF-YB Ll.50-139 was not significantly different than the decrease in CAT activity observed by the transfection of 2 µg of Gal4. 
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EnGSp, which contains a Gal4 DNA binding site in-
serted into the FGF-4 enhancer, Gal4/NF-YB ~50-
139 induced a small increase (approximately four- to 
fivefold) in reporter gene activity, whereas Gal4/NF-
YA 1-261 and Gal4/NF-YC ~1 induced approxi-
mately 15- and 50-fold increases in reporter gene ac-
tivity, respectively (data not shown). Together, these 
results argue that the individual subunits of NF-Y are 
not sufficient to repress FGF-4 promoter activity. 
The Orientation and the Position Are Important 
for CCAAT Box Function 
Because none of the three subunits of NF-Y ap-
peared to repress the FGF-4 promoter on their own 
and all three subunits are required for binding to 
DNA, we considered the possibility that repression 
by NF-Y may be architectural in nature. In this re-
gard, analysis of bona fide NF-Y binding CCAAT 
boxes demonstrated that CCAAT boxes of TATA-
containing promoters are most often located between 
80 and 100 bp upstream of the transcription start site 
(52). In addition, NF-Y has been shown to bend DNA 
60-80° (46,72). To determine whether the orientation 
and/or the position of the CCAAT box in the FGF-4 
promoter influence its function, we generated a set of 
promoter/reporter gene constructs in which the wild-
type CCAAT box sequence was replaced with a 
CCAA T box of the opposite orientation (reversed 
CCAA T +E and reversed CCAAT) (Fig. 7 A). In an-
other set of promoter/reporter gene constructs, the 
CCAA T box sequence was moved from its wild-type 
position (-101 to - ll 1) to an upstream position 
(-306 to -296) within the FGF-4 promoter (upstream 
CCAAT+E and upstream CCAAT). The sequence 
used to change the orientation and the position of the 
CCAA T box consisted of 11 nucleotides that in-
cluded the CCAAT pentanucleotide plus three 5'- and 
three 3'-flanking bp. These 11 bp constitute an NF-Y 
consensus site that has been derived from both func-
tional and statistical studies (7,52). These promoter/ 
reporter gene constructs were tested in F9 EC cells 
to examine the effect of the orientation and the posi-
tion on the function of the CCAA T box in both the ;-. 
presence and the absence of the FGF-4 enhancer. In 
the presence of the FGF-4 enhancer, reversing the 
orientation of the CCAAT box resulted in reporter 
gene activity similar to that of the wild-type pro-
moter/reporter gene construct (Fig. 7B). In contrast, 
moving the CCAAT box to an upstream site led to a 
decrease in reporter gene activity, to levels similar to 
those with CCAATmut+E. Therefore, when the FGF-
4 enhancer is present, the FGF-4 CCAAT box can 
function in either orientation to positively affect pro-
moter activity. In direct contrast, when the FGF-4 
enhancer is absent, either reversing the orientation of 
the CCAAT box or moving the CCAA T box up-
stream neutralized its ability to repress the FGF-4 
promoter (Fig. 7C). Therefore, both the orientation 
and the position of the CCAAT box are important 
for the CCAAT box to function as a negative cis-
regulatory element in the absence of the FGF-4 en-
hancer. Collectively these results demonstrate that 
both the orientation and the position of the CCAAT 
box influence its ability to properly regulate the FGF-
4 promoter and argue for an architectural role by the 
CCAAT box in FGF-4 promoter repression. 
DISCUSSION 
The work described in this study demonstrates that 
the CCAAT box of the FGF-4 promoter can function 
as a positive cis-regulatory element in the presence 
of an active FGF-4 enhancer or function as a nega-
tive cis-regulatory element when the FGF-4 enhancer 
is inactive. Previous studies have shown that NF-Y 
mediates the positive effect of the CCAAT box of the 
FGF-4 promoter in F9 EC cells (41). In this study, 
we demonstrate that NF-Y mediates the repressive ef-
fect of this CCAA T box and that the status of the 
FGF-4 enhancer determines whether NF-Y activates 
or represses the FGF-4 promoter. In addition, we show 
that NF-Y associates with the endogenous FGF-4 pro-
moter in both F9 EC cells and F9-differentiated cells. 
Studies to determine how NF-Y mediates repression 
demonstrate that the individual subunits of NF-Y are 
not sufficient for repression, and that the orientation 
and the position of the CCAAT box are important for 
its ability to repress the FGF-4 promoter. 
Differentiation of EC cells results in the downregu-
lation of FGF-4 transcription (64,69,82,86). Al-
though previous studies have suggested that the FGF-
4 enhancer is inactivated after EC cells differentiate 
(17,50), it was unclear whether the enhancer is com-
pletely inactivated after differentiation or whether the 
function of the FGF-4 promoter is actively repressed 
after differentiation. We demonstrate here that the 
FGF-4 enhancer is incapable of activating the heter-
ologous TK promoter in F9-differentiated cells. The 
most likely explanation for the loss of FGF-4 en-
hancer activity is the loss of Sox2 and Oct-3 expres-
sion that occurs with differentiation (56,87). In this 
regard, Sox2 and Oct-3 bind cooperatively to the DS-
HMG and POU motifs to synergistically activate 
transcription of the FGF-4 gene (1,2,59,87), and both 
Sox2 and Oct-3 mRNA are nearly undetectable 72 h 
after EC cells have been induced to differentiate 
(56,87). Unlike Sox2 and Oct-3, the transcription fac-
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Figure 7. The orientation and the position of the CCAAT box is important for the regulation of the FGF-4 promoter. (A) Physical map of 
the promoter/reporter gene constructs that contain a reversed or upstream CCAAT box. (B) Transfection of F9 EC cells with 15 µg of 
427T+E, CCAATmut+E, invert CCAAT+E, and upstream CCAAT+E. Results are presented as CAT expression relative to the activity 
of 427T +E, which was set to I. This experiment was performed five times. The data shown are the compilation of the five experiments, 
and the standard deviation for each condition is represented by error bars. Analysis of the data by the Student's 1-test indicated that the 
activity of CCAATmut+E and upstream CCAATmut+E was significantly less than the activity of 427T +E with a p-value of less than 0.05, 
whereas the activity of reversed CCAAT +E was not significantly different than the activity of 427T +E. (C) Transfection of F9 EC cells 
with 15 µg of 427T, CCAATmut, invert CCAAT and upstream CCAAT. Results are presented as fold induction over the activity of 427T, 
which was set to I. This experiment was performed four times. The data shown are the compilation of the four experiments, and the standard 
deviation for each condition is represented by error bars. Analysis of the data by the Student's 1-test indicated that the activity of CCAATmut, 
reversed CCAATmut, and upstream CCAATmut were significantly greater than the activity of 427T with a p-value of less than 0.05. 
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mater are expressed before and after EC cells differ-
entiate and differentiation does not significantly alter 
their binding to DNA in vitro ( 41,42). 
Examination of the FGF-4 promoter led to the sur-
prising finding that the promoter is subject to repres-
sion in the absence of a functional FGF-4 enhancer. 
More specifically, we show that disruption of the 
CCAAT box results in an increase in FGF-4 pro-
moter activity in F9 EC cells in the absence of the 
FGF-4 enhancer and in F9-differentiated cells where 
the FGF-4 enhancer is inactive. The increased FGF-
4 promoter activity (four- to fivefold) that is observed 
when the CCAAT box is disrupted in F9 EC cells, 
relative to the increase that is observed in differenti-
ated cells (twofold) where the enhancer is inactive, is 
most likely the result of other changes that occur 
within the promoter after differentiation. Moreover, 
it appears that the GC boxes are not involved in the 
repression of the FGF-4 promoter, and the GC boxes 
are not required by the CCAA T box to mediate re-
pression. These latter findings are of particular inter-
est, because neighboring cis-regulatory elements are 
involved with CCAAT boxes in the repression of 
other promoters. Specifically, the CCAAT box of the 
RUSH/SMARCA3 promoter is only repressive in 
conjunction with two upstream Spl sites (29), while 
the CCAA T box of the growth hormone receptor pro-
moter is involved in the recruitment of a "represso-
some" complex that involves several neighboring cis-
regulatory elements (27). 
Like the CCAAT box of the FGF-4 promoter, the 
CCAA T boxes of several cell cycle-dependent pro-
moters also function in a context-dependent manner. 
Cyclin Bl, B2, cdc25, and cdc2 are all required for 
progression through the G2 phase of the cell cycle. 
The promoters of these genes contain CCAAT boxes 
that positively modulate their activity through the 
progression of the cell cycle (8,24,80,91). However, 
during p53-induced G2 arrest, the CCAAT boxes of 
these promoters negatively regulate the transcription 
of these genes (51,89). Therefore the regulation of 
the cyclin Bl, B2, cdc25, and cdc2 promoters by the 
CCAA T box is dependent upon the cell cycle. How-
ever, the mechanism involved remains to be deter-
mined. Our studies indicate that the regulation of the 
FGF-4 promoter by the CCAAT box is dependent 
upon the FGF-4 enhancer, which is located more 
than 3 kb downstream from the FGF-4 promoter 
CCAAT box. Furthermore, our results demonstrate 
that disruption of the DSHMG motif, the DSHMG 
and POU motifs, or the GT box in the enhancer is 
sufficient to convert the CCAA T box from a positive 
to a negative cis-regulatory element. The effects of 
disrupting the DSHMG and POU motifs are particu-
larly interesting, because Sox2 and Oct-3 synergisti-
cally activate transcription by binding to these cis-
regulatory elements in the FGF-4 enhancer (1,59,87). 
Moreover, p300 has been shown to mediate the ef-
fects of Sox2 and Oct-3 on gene transcription (58, 
59), and p300 is associated with the endogenous 
FGF-4 enhancer in F9 EC cells (58). This led us to 
examine the effect of p300 on the function of the 
CCAAT box by physically tethering p300 to the disa-
bled FGF-4 enhancer in 427T +EnGSp. Our results 
demonstrate that p300 can convert the CCAAT box 
in the disabled FGF-4 enhancer from a negative to a 
positive cis-regulatory element. Together, our find-
ings argue that the FGF-4 enhancer strongly influ-
ences the behavior of the CCAAT box and further 
suggest that p300 is likely to mediate, at least in part, 
the positive influence of the FGF-4 enhancer on the 
promoter CCAAT box. 
Previous work utilizing the dominant negative NF-
y A29 has shown that NF-Y is functionally involved 
in the activation of the FGF-4 promoter (41). In this 
study, NF-Y A29 was used to demonstrate that NF-Y 
can function to repress the FGF-4 promoter when the 
FGF-4 enhancer is either absent or inactive. NF-
y A29 has been utilized by others to show that NF-Y 
mediates the repression of certain cell cycle-depen-
dent promoters during p53-induced G2 arrest and the 
repression of the growth hormone receptor promoter 
(27,51,89). NF-Y is one of several bifunctional tran-
scription factors that include the nonsteroidal nuclear 
receptors, YYl and NF-KB. The context of bifunc-
tional transcription factors dictates whether they acti-
vate or repress transcription. NF-Y functions as a bi-
functional transcription factor in the regulation of 
several cell cycle-dependent promoters. In the case of 
the von Willebrand factor promoter, NF-Y binds to 
the canonical CCAA T box of the von Wille brand fac-
tor promoter in endothelial cells to activate transcrip-
tion, whereas in nonendothelial cells, NF-Y binds to 
a noncanonical NF-Y binding site in this promoter to 
repress transcription (62). 
NF-Y has been reported to mediate repression and 
several mechanisms appear to be utilized. In the case 
of the growth hormone receptor promoter, NF-Y has 
been shown to be part of a "repressosome" complex 
that interacts with the co-repressor mSin3b (27). In 
addition, NF-Y has been shown to interact with the 
co-repressor, HDAC 1, in the regulation of at least 
two promoters (63,75). The interaction of NF-Y with 
either coactivators or co-repressors in response to dif-
ferent signals appears to parallel the bifunctional ac-
tion of nuclear hormone receptors, which associate 
with coactivators in the presence of hormone and ac-
tivate transcription, but associate with co-repressors 
in the absence of hormone and inhibit transcription 
(65). Consequently, this prompted us to examine by 
208 
ChIP analyses whether HDACI is associated with the 
FGF-4 promoter in F9-differentiated cells. We were 
unable to show enrichment of the FGF-4 promoter 
with antibodies that recognize HDACl. However, 
this negative result does not rule out the possibility 
that HDACI or another co-repressor associates with 
the FGF-4 promoter in differentiated EC cells. NF-
y may also function by influencing the binding of 
transcription factors to neighboring cis-regulatory el-
ements. In this regard, the binding of NF-Y to DNA 
can induce bends of 60-80° in the DNA (46,72). 
Thus, NF-Y could act as an architectural factor to 
enhance transcription by increasing the affinity of 
factors that bind to adjacent cis-regulatory elements, 
as it does in the cases of Spl, SREBPl, and RF-X 
binding to four different promoters. (33,67,71,84). 
Similarly, NF-Y could to repress transcription by ste-
rically blocking the binding of activating transcrip-
tion factors to adjacent regulatory regions as it does 
in the insulin gene and the renin gene (22,76). 
Our studies demonstrate that the individual NF-Y 
subunits are not sufficient to mediate repression of 
the FGF-4 promoter, which suggests that multiple 
subunits of NF-Y are required for repression. In this 
regard, recruitment of a co-repressor may require a 
binding surface that is formed by two or more of the 
NF-Y subunits. For example, all three subunits of 
NF-Y are required to interact with the stern! regula-
tory element binding protein, a transcription factor 
involved in cholesterol and fatty acid metabolism 
(20). Alternatively, repression by NF-Y may be a re-
sult of NF-Y binding to and bending DNA, thereby 
altering the architecture of the promoter. For this rea-
son, we examined the effect of altering the orienta-
tion and the position of the CCAAT box on its ability 
to regulate the FGF-4 promoter. We show that the 
CCAAT box can activate the FGF-4 promoter in ei-
ther orientation in the presence of the FGF-4 en-
hancer, but it is unable to activate when it is moved 
almost 200 bp upstream of its wild-type position. The 
ability of the CCAAT box to activate transcription 
regardless of orientation is not surprising considering 
that CCAAT boxes are found throughout the genome 
in either orientation, with roughly 60% of CCAAT 
boxes being in the inverted ATTGG orientation (52). 
The loss of function when the CCAAT box is moved 
to an upstream position within the promoter may re-
flect the need for the CCAAT box to be within an 
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optimal distance of the TAT A box. In promoters that 
contain both a CCAAT box and a TAT A box, the 
CCAA T box is found most often between 80 and l 00 
bp upstream of the transcription start site (52). In ad-
dition, NF-Y has been shown to interact with compo-
nents of the basal transcriptional machinery (5,16, 
26). Although changing the orientation of the CCAAT 
box does not alter its function when the FGF-4 en-
hancer is active, this is not the case when the FGF-4 
enhancer is absent. In the absence of the enhancer, 
the CCAAT box fails to inhibit the FGF-4 promoter 
if its orientation is reversed or if the CCAAT box is 
moved to an upstream position. These results suggest 
that the ability of NF-Y to repress the FGF-4 pro-
moter is strictly dependent upon the orientation and 
the position of the CCAA T box. Previous studies 
have suggested that the CCAAT box and NF-Y may 
play a structural role in gene regulation (46,52,72); 
our findings provide direct evidence for an architec-
tural role of NF-Yin the case of the FGF-4 promoter. 
In conclusion, our studies provide evidence that 
the CCAAT box of the FGF-4 promoter can activate 
or repress transcription. We show that the FGF-4 en-
hancer, and more specifically p300, regulates the 
function of the CCAAT box. Moreover, our findings 
provide both functional and physical evidence that 
NF-Y mediates the effect of the CCAA T box in both 
F9 EC cells and F9-differentiated cells. Finally, we 
demonstrate that orientation and position of the 
CCAAT box are important and argue for an architec-
tural role by the CCAAT box and NF-Y in the regula-
tion of the FGF-4 promoter. Given these findings, the 
system described in this study appears to provide an 
excellent model for exploring the architectural role of 
CCAAT boxes and for investigating the bifunctional 
behavior of NF-Y and its regulation of genes that 
play key roles during mammalian development. 
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